CN110559467A - Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing - Google Patents
Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing Download PDFInfo
- Publication number
- CN110559467A CN110559467A CN201810577024.1A CN201810577024A CN110559467A CN 110559467 A CN110559467 A CN 110559467A CN 201810577024 A CN201810577024 A CN 201810577024A CN 110559467 A CN110559467 A CN 110559467A
- Authority
- CN
- China
- Prior art keywords
- micro
- magnesium hydride
- nano
- dressing
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910012375 magnesium hydride Inorganic materials 0.000 title claims abstract description 56
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract 19
- 239000011858 nanopowder Substances 0.000 claims abstract description 22
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 20
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 229910052709 silver Inorganic materials 0.000 claims description 8
- 239000004332 silver Substances 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 239000012209 synthetic fiber Substances 0.000 claims description 2
- 229920002994 synthetic fiber Polymers 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 2
- 229920006254 polymer film Polymers 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract description 5
- 239000000347 magnesium hydroxide Substances 0.000 abstract description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract description 5
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 230000006698 induction Effects 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 2
- 238000005286 illumination Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000009916 joint effect Effects 0.000 abstract 1
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 description 33
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- -1 silver ions Chemical class 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010054923 Inflammation of wound Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/50—Lubricants; Anti-adhesive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/424—Anti-adhesion agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing which comprises an effective antibacterial and anti-inflammatory component magnesium hydride MgH2micro-nano powder, auxiliary materials and a dressing matrix; the surface and/or the interior of the dressing matrix is uniformly loaded and coated with the magnesium hydride micro-nano powder. When meeting wound exudate, the magnesium hydride micro-nano powder immediately absorbs moisture and reacts to be converted into micro-nano magnesium hydroxide particles, and meanwhile, the magnesium hydride micro-nano powder causes local alkalescence, and has broad-spectrum bactericidal property and better biocompatibility without illumination induction. Meanwhile, the hydrogen released by the reaction has the characteristics of no toxicity and inflammation diminishing, and certain prevention of wound adhesionAnd (4) performing joint action. Convenient storage and use, safety, environmental protection, antibiosis, antiphlogosis, infection prevention and contribution to wound surface repair.
Description
Technical Field
The invention relates to medical wounds and wound dressings, in particular to a safe and environment-friendly micro-nano magnesium hydride dressing with an antibacterial and anti-inflammatory function.
Background
After human skin is injured, tissue necrosis and blood vessel rupture bleeding occur on the wound part to different degrees, and inflammatory reaction appears within hours, which is manifested by congestion, serous fluid exudation and leukocyte migration. The body has a series of biochemical processes that attempt to repair and rebuild, the basic processes including the hemostasis, inflammation, cell proliferation, and maturation and remodeling stages. During this repair, medical dressings often play an important role as a covering for the wound site: can temporarily replace partial function of the skin barrier, and provides a favorable microenvironment for wound healing; meanwhile, the medicine also has the effects of controlling wound secretion, stopping bleeding, inhibiting wound infection, reducing or removing scar formation, accelerating healing and repairing and the like.
In order to avoid the influence of bacterial infection and inflammation of wounds on wound repair, antibacterial components are often added into medical dressings. At present, silver ions, chitin/chitosan, bactericidal drugs and the like are common in the market. However, silver-based antibacterial agents are expensive in raw materials, high in cost, poor in antifungal and antifungal effects, silver is not an essential element for human bodies, and is poor in-vivo biological safety and biocompatibility, and the environmental safety is also damaged when the silver-based antibacterial agents are used. The bacteriostatic ability of the chitin/chitosan natural antibacterial agent is strong in dependence on the pH of the surrounding environment and weak in inhibition ability on gram-negative bacteria. However, the common bactericidal drugs are easy to generate drug resistance and have side effects.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides the safe, environment-friendly and good-biocompatibility micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing with the antibacterial and anti-inflammatory functions. It is characterized in that the micro-nano magnesium hydride MgH2Can be used as additive of common dressing matrix and effective component for resisting bacteria and diminishing inflammation. When the micro-nano magnesium hydride meets wound exudate, the micro-nano magnesium hydride immediately absorbs moisture and reacts MgH2+2H2O→Mg(OH)2+2H2↑
The micro-nano magnesium hydroxide particles generated by the reaction conversion have obvious antibacterial function, the specific surface area is large, microorganisms can be easily adsorbed, and simultaneously, reactive oxygen free radicals ROS generated around the particles can damage the cell wall structure of bacteria so as to rapidly kill the bacteria. Furthermore, according to the endocytosis-dissociation mechanism, Mg (OH)2The micro-nano particles can enter the interior of bacterial cells through endocytosis and release OH in an aqueous environment-Disruption of the normal pH microenvironment, causing chemical denaturation of nucleic acids and proteins, resulting in bacterial deathAnd (7) death. The micro-nano magnesium hydroxide particles have high antibacterial efficiency and broad-spectrum bactericidal property, and can be carried out in the dark independent of a light source. And the degradation product magnesium ions are a major element necessary for human bodies, and the biological safety is high.
Meanwhile, the reaction also releases nontoxic hydrogen, so that on one hand, oxygen is isolated near the wound to cause a low-oxygen environment, the growth of oxygen consuming bacteria is further inhibited, and meanwhile, the physical action of gas release can be reduced to a certain extent to prevent the wound from being adhered; on the other hand, hydrogen has a definite anti-inflammatory effect, and has no side effects of hormones and aspirin drugs, so that the hydrogen is beneficial to the inflammation diminishing of the wound surface and the recovery of the wound, and meanwhile, researches and reports that the hydrogen also has the effects of eliminating and preventing scars.
The purpose of the invention is realized by the following technical scheme:
The invention provides a micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing which comprises magnesium hydride MgH2Micro-nano powder (effective antibacterial and anti-inflammatory component), auxiliary materials and dressing matrix; the surface and/or the interior of the dressing matrix is uniformly loaded and coated with the magnesium hydride micro-nano powder.
preferably, the size of the magnesium hydride micro-nano powder is 10nm-10 mu m. The smaller the size of the magnesium hydride micro-nano powder is, the higher the sterilization efficiency is. Above 10 μm, the sterilizing effect is remarkably reduced, while below 10nm, the manufacturing cost is rapidly increased, and the biosafety may be adversely affected to some extent due to the small size.
Preferably, the magnesium hydride micro-nano powder is loaded on the surface and/or inside of the dressing matrix in an amount of 1 mu g-1 mg/square centimeter of dressing. When the loading of the magnesium hydride micro-nano powder is less than 1 microgram/square centimeter, the MIC (minimum inhibitory concentration) of most wound infection bacteria is not reached; when the concentration is more than 1 mg/square centimeter, on one hand, the concentration far exceeds the required bacteriostatic MIC, which is waste, and on the other hand, the alkaline environment, hydrogen and local released heat generated by reaction are too high, which is not beneficial to healing the wound surface as soon as possible.
Preferably, the amount of hydrogen gas generated by the dressing in use is 0.0018-1.8 mL/cm of dressing. When the amount of generated hydrogen is less than 0.0018 mL/square centimeter, the wound adhesion cannot be sufficiently prevented; when the concentration is more than 1.8 mL/square centimeter, the gas production and the local released heat in reaction are too high, which is not beneficial to healing the wound as soon as possible.
Preferably, the dressing matrix can be one or two of natural gauze, synthetic fiber non-woven fabric, foamed polymer membrane, hydrogel, alginate, agarose, collagen/gelatin and chitin/chitosan membrane.
Preferably, the auxiliary materials comprise medicinal adhesives, ointment matrixes, medical hydrogel and the like.
Preferably, the magnesium hydride micro-nano powder as the effective antibacterial and anti-inflammatory component can be mixed with other common antibacterial agents to be loaded and coated on the surface and/or inside of the dressing matrix so as to be used for synergistic antibacterial and anti-inflammatory effects.
Preferably, the other common antibacterial agent can be one or more of inorganic antibacterial agent and organic antibacterial agent.
More preferably, the inorganic antibacterial agent comprises silver, copper, nano zinc oxide, nano titanium dioxide; the organic antibacterial agent comprises quaternary ammonium salt antibacterial agent and chitosan.
Compared with the prior art, the invention has the following beneficial effects:
1. The magnesium hydride micro-nano powder in the wound dressing disclosed by the invention immediately absorbs moisture when meeting wound exudates and reacts to be converted into micro-nano magnesium hydroxide particles, and meanwhile, local alkalescence is caused, so that the magnesium hydride micro-nano powder has broad-spectrum bactericidal property without light induction and better biocompatibility; meanwhile, the hydrogen released by the reaction has the characteristics of no toxicity and inflammation diminishing, and has certain effect of preventing wound adhesion.
2. The wound dressing is convenient to store and use, safe, environment-friendly, antibacterial, anti-inflammatory and anti-infection, and is beneficial to wound surface repair.
3. Compared with the common method of loading silver ions, chitin/chitosan and a bactericidal drug in the prior art, the method has obvious advantages. Compared with silver antibacterial agents, the biological safety and compatibility are obviously superior, the environment is friendly, and the cost is lower; compared with chitin/chitosan natural antibacterial agents, the broad-spectrum bactericidal agent has better broad-spectrum bactericidal property, more obvious bactericidal effect on gram-negative bacteria and no obvious dependence on the pH value of the surrounding environment; compared with common broad-spectrum antibiotic medicines such as gentamicin, vancomycin and the like, the compound has no drug resistance to bacteria and no obvious side effect.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
EXAMPLE 1
The nanometer magnesium hydride with the grain diameter of 10-100nm is evenly dispersed in the melted polyethylene according to 2% w/v, and the solution is processed into the polyvinyl non-woven fabric dressing of the composite nanometer magnesium hydride by the technological processes of spinning, laying, hot-pressing, rolling and the like. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 5 mu g/square centimeter of the dressing; the amount of hydrogen gas generated by the dressing in use is 0.0086 mL/square centimeter of dressing.
The dressing is subjected to an in vitro antibacterial experiment, and the 24-hour bacteriostasis rate of the dressing on representative gram-positive staphylococcus aureus and gram-negative escherichia coli is over 95 percent. The toxicity of the in vitro fibroblast is 0-1 grade shown by toxicity experiments, and the survival and proliferation rate of the fibroblast is more than 90 percent.
Example 2
Uniformly dispersing the nano magnesium hydride with the particle size of 200-1000nm in an absolute ethyl alcohol solution containing 1% of silane coupling agent according to 10% w/v, immersing the activated natural gauze into the solution for 15 minutes, pulling and taking out the activated natural gauze, drying the activated natural gauze at 50 ℃, and continuing to dry the activated natural gauze for 24 hours at the vacuum normal temperature. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 50 mug/square centimeter of the dressing; the amount of hydrogen gas generated by the dressing in use is 0.086mL per square centimeter of dressing.
The dressing is subjected to an animal (rabbit) body antibacterial experiment, and the bacteriostatic rates of the dressing to staphylococcus aureus, staphylococcus epidermidis and escherichia coli within 72 hours are all more than 95%. The wound healing rate was about 25% faster than the control polyvinyl nonwoven dressing.
Example 3
Uniformly dispersing micro-nano magnesium hydride with the particle size of 500nm-10 mu m in absolute ethyl alcohol according to 15% w/v to prepare a solution, uniformly spraying the solution on the surface of a chitosan film dressing matrix, drying at 50 ℃, and then continuously drying for 24 hours at the normal temperature in vacuum. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 350 mug/square centimeter of the dressing; the amount of hydrogen gas generated by the dressing in use was 0.6mL per square centimeter of the dressing.
The results of in vitro antibacterial experiments show that the 24-hour bacteriostasis rates of the chitosan film dressing matrix without spraying of nano magnesium hydride on gram-positive staphylococcus aureus and gram-negative escherichia coli are respectively 78% and 63%, and the bacteriostasis rates are increased to 99% after spraying of nano magnesium hydride. The toxicity of the in vitro fibroblast is 0-1 grade shown by toxicity experiments, and the survival and proliferation rate of the fibroblast is more than 90 percent.
Example 4
Uniformly dispersing 500nm nano magnesium hydride with the particle size of 100-. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 0.8 mg/square centimeter of dressing; the amount of hydrogen gas generated by the dressing in use was 1.4mL per square centimeter of dressing.
The dressing is subjected to an animal (rabbit) body antibacterial experiment, and the bacteriostatic rates of the dressing to staphylococcus aureus, staphylococcus epidermidis and sex escherichia coli within 72 hours are all over 99.9 percent.
Example 5
Uniformly dispersing nano magnesium hydride with the particle size of 50-100nm in absolute ethyl alcohol according to 8% w/v to prepare a solution, uniformly spraying the solution on the surface of a collagen dressing matrix, drying at 50 ℃, and continuously drying for 24 hours at the vacuum normal temperature. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 100 mu g/square centimeter of the dressing; the amount of hydrogen gas generated by the dressing in use was 0.17mL per square centimeter of the dressing.
The results of in vitro antibacterial experiments show that the 24-hour bacteriostasis rate of the collagen dressing matrix which is not sprayed with nano magnesium hydride on gram-positive staphylococcus aureus and gram-negative escherichia coli is almost 0 (-2%), and the bacteriostasis rate is increased to more than 99% after the nano magnesium hydride is sprayed. The toxicity of the in vitro fibroblast is 0 grade shown by toxicity experiments, and the survival and proliferation rate of the fibroblast is more than 95 percent.
Example 6
Uniformly dispersing micro-nano magnesium hydride with the particle size of 500-5 mu m in organic silica gel water according to 3% w/v and nano zinc oxide with the particle size of 100-200nm according to 1% w/v, coating a layer of the composite glue on the surface of the alginate dressing matrix, and curing at normal temperature for more than 24 hours. The amount of the corresponding magnesium hydride micro-nano powder loaded on the dressing matrix is 20 mug/square centimeter of the dressing; the amount of hydrogen gas generated by the dressing in use was 0.035 mL/cm.
The dressing is subjected to an animal (rabbit) body antibacterial experiment, the bacteriostasis rate of the dressing to staphylococcus aureus, staphylococcus epidermidis and escherichia coli in 24 hours is over 99 percent, and meanwhile, no obvious hyperplasia or scar is generated during wound healing.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Claims (8)
1. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing is characterized by comprising micro-nano magnesium hydride powder, auxiliary materials and a dressing matrix; the surface and/or the interior of the dressing substrate is loaded and coated with the magnesium hydride micro-nano powder.
2. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing of claim 1, wherein the micro-nano powder of magnesium hydride is 10nm to 10 μm in size.
3. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing of claim 1, wherein the magnesium hydride micro-nano powder is loaded on the surface and/or inside of the dressing substrate in an amount of 1 μ g-1 mg/cm.
4. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing of claim 1, wherein the amount of hydrogen generated by the dressing in use is 0.0018-1.8 mL/cm.
5. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing of claim 1, wherein the dressing matrix is one or a combination of two of natural gauze, synthetic fiber non-woven fabric, foamed poly-polymer film, hydrogel, alginate, agarose, collagen/gelatin, chitin/chitosan film.
6. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing as claimed in claim 1, wherein the wound dressing further comprises an antibacterial agent, and the antibacterial agent is mixed with the micro-nano magnesium hydride powder and is loaded and coated on the surface and/or inside the dressing substrate.
7. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing as claimed in claim 6, wherein the antibacterial agent is one or more of an inorganic antibacterial agent and an organic antibacterial agent.
8. The micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing as claimed in claim 7, wherein the inorganic antibacterial agent comprises silver, copper, nano zinc oxide, nano titanium dioxide; the organic antibacterial agent comprises quaternary ammonium salt antibacterial agent and chitosan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810577024.1A CN110559467A (en) | 2018-06-06 | 2018-06-06 | Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810577024.1A CN110559467A (en) | 2018-06-06 | 2018-06-06 | Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110559467A true CN110559467A (en) | 2019-12-13 |
Family
ID=68772037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810577024.1A Pending CN110559467A (en) | 2018-06-06 | 2018-06-06 | Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559467A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112210091A (en) * | 2020-10-29 | 2021-01-12 | 吉林大学 | Multifunctional natural polysaccharide repairing adhesive hydrogel, preparation method and application of multifunctional natural polysaccharide repairing adhesive hydrogel in preparation of medicines for treating skin injury |
| CN113440640A (en) * | 2021-06-23 | 2021-09-28 | 南京大学 | Algae-bacterium gel dressing and preparation method thereof |
| CN113616671A (en) * | 2020-05-09 | 2021-11-09 | 上海交通大学 | Micro-nano MgH2Use of compound particles for inhibiting leishmanial infections and treating leishmaniasis |
| CN113648326A (en) * | 2021-08-01 | 2021-11-16 | 杭州氢源素生物科技有限公司 | Disinfectant containing nano particles and capable of inactivating viruses and preparation method thereof |
| CN114470300A (en) * | 2022-03-28 | 2022-05-13 | 浙江蓝禾医疗用品有限公司 | Fluorescent nano dressing and preparation method thereof |
| CN114699342A (en) * | 2022-04-29 | 2022-07-05 | 中国人民解放军空军军医大学 | Lipstick with effects of moisturizing, repairing and preventing and treating desquamation and preparation method thereof |
| CN114948991A (en) * | 2021-02-26 | 2022-08-30 | 复旦大学 | Application of magnesium hydride in preparation of medicine for preventing and treating ocular surface inflammation related to xerophthalmia |
| CN115382001A (en) * | 2022-08-04 | 2022-11-25 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of skin repair fiber membrane |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357061A (en) * | 2013-06-24 | 2013-10-23 | 扬州辐照中心 | Production method of surgical dressing by irradiation sterilization |
| JP2015054074A (en) * | 2013-09-11 | 2015-03-23 | 恵和株式会社 | Adhesive bandage |
| CN209392452U (en) * | 2018-06-06 | 2019-09-17 | 上海交通大学 | A kind of micro-nano magnesium hydride antibacterial anti-inflammatory wound dressing |
-
2018
- 2018-06-06 CN CN201810577024.1A patent/CN110559467A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357061A (en) * | 2013-06-24 | 2013-10-23 | 扬州辐照中心 | Production method of surgical dressing by irradiation sterilization |
| JP2015054074A (en) * | 2013-09-11 | 2015-03-23 | 恵和株式会社 | Adhesive bandage |
| CN209392452U (en) * | 2018-06-06 | 2019-09-17 | 上海交通大学 | A kind of micro-nano magnesium hydride antibacterial anti-inflammatory wound dressing |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616671A (en) * | 2020-05-09 | 2021-11-09 | 上海交通大学 | Micro-nano MgH2Use of compound particles for inhibiting leishmanial infections and treating leishmaniasis |
| WO2021227572A1 (en) * | 2020-05-09 | 2021-11-18 | 上海交通大学 | Use of micro-nano mgh2 compound particles in inhibition of leishmania infection and treatment of leishmaniasis |
| CN113616671B (en) * | 2020-05-09 | 2022-06-28 | 上海交通大学 | Micro-nano MgH2Application of compound particles in preparation of medicines for inhibiting leishmania infection and treating leishmania |
| CN112210091A (en) * | 2020-10-29 | 2021-01-12 | 吉林大学 | Multifunctional natural polysaccharide repairing adhesive hydrogel, preparation method and application of multifunctional natural polysaccharide repairing adhesive hydrogel in preparation of medicines for treating skin injury |
| CN114948991A (en) * | 2021-02-26 | 2022-08-30 | 复旦大学 | Application of magnesium hydride in preparation of medicine for preventing and treating ocular surface inflammation related to xerophthalmia |
| CN113440640A (en) * | 2021-06-23 | 2021-09-28 | 南京大学 | Algae-bacterium gel dressing and preparation method thereof |
| CN113440640B (en) * | 2021-06-23 | 2022-07-22 | 南京大学 | Algae-bacterium gel dressing and preparation method thereof |
| CN113648326A (en) * | 2021-08-01 | 2021-11-16 | 杭州氢源素生物科技有限公司 | Disinfectant containing nano particles and capable of inactivating viruses and preparation method thereof |
| CN113648326B (en) * | 2021-08-01 | 2023-11-07 | 武汉启航科技发展有限公司 | Nanoparticle-containing virus-inactivated disinfectant and preparation method thereof |
| CN114470300A (en) * | 2022-03-28 | 2022-05-13 | 浙江蓝禾医疗用品有限公司 | Fluorescent nano dressing and preparation method thereof |
| CN114699342A (en) * | 2022-04-29 | 2022-07-05 | 中国人民解放军空军军医大学 | Lipstick with effects of moisturizing, repairing and preventing and treating desquamation and preparation method thereof |
| CN115382001A (en) * | 2022-08-04 | 2022-11-25 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of skin repair fiber membrane |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110559467A (en) | Micro-nano magnesium hydride antibacterial and anti-inflammatory wound dressing | |
| Mohandas et al. | Chitosan based metallic nanocomposite scaffolds as antimicrobial wound dressings | |
| Nguyen et al. | Biomedical materials for wound dressing: Recent advances and applications | |
| Konop et al. | Certain aspects of silver and silver nanoparticles in wound care: a minireview | |
| KR101377569B1 (en) | Antimicrobial Wound Dressing and Preparing Method of the Same | |
| Politano et al. | Use of silver in the prevention and treatment of infections: silver review | |
| EP3226921B1 (en) | Antimicrobial compositions comprising bioglass | |
| ES2441266T3 (en) | Methods for producing antimicrobial wet wound dressings attached to silver and wet wound dressings produced by such methods | |
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN101596325A (en) | Nano-silver biological sponge and preparation method thereof | |
| Li et al. | Antibacterial strategies for wound dressing: preventing infection and stimulating healing | |
| EP3451829B1 (en) | Anti-microbial compositions | |
| CN101954117A (en) | Hemostatic bacteriostatic biological dressing and preparation method thereof | |
| Mirhaj et al. | An overview on the recent advances in the treatment of infected wounds: Antibacterial wound dressings | |
| CN108030774B (en) | Carboxymethyl chitosan nano-microsphere loaded with photodynamic bactericidal drug and synthetic method thereof | |
| Farazin et al. | Natural biomarocmolecule-based antimicrobial hydrogel for rapid wound healing: A review | |
| EP3040087B1 (en) | Wound dressings | |
| CN209392452U (en) | A kind of micro-nano magnesium hydride antibacterial anti-inflammatory wound dressing | |
| EP3378503A2 (en) | Calcium based clinical material with antimicrobial properties and method of forming for prevention or treatment of infection | |
| Nikdel et al. | Fabrication of cellulosic nonwoven material coated with polyvinyl alcohol and zinc oxide/mesoporous silica nanoparticles for wound dressing purposes with cephalexin delivery | |
| TW202120132A (en) | A composite fiber | |
| CN110859989A (en) | Liquid band-aid and preparation method thereof | |
| Ndlovu et al. | Dissolvable zinc oxide nanoparticle-loaded wound dressing with preferential exudate absorption and hemostatic features | |
| CN201676083U (en) | Active silver ion antiseptic dressing for curing burns, scalds and wounds | |
| US20100087769A1 (en) | Biocidic medical devices, implants and wound dressings |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |